Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: The objective of this study was to elucidate associations between adiposity reduction and changes in HbA1c and insulin use among adults with type 2 diabetes and overweight or obesity.
Methods: Changes in BMI, waist circumference, and total percent fat mass were obtained over 8 years among 1316 individuals (aged 45-76 years) enrolled in the Look AHEAD (Action for Health in Diabetes) clinical trial of weight loss. Generalized linear models were used to assess relationships between 5% decreases in adiposity measures with glycated hemoglobin (HbA1c) and insulin use over time.
Results: A 5% reduction in total percent fat was associated with 0.15% (95% CI: 0.12%-0.18%) lower mean HbA1c. Similarly, 5% reductions in waist circumference and BMI were also associated with slightly lower mean HbA1c: 0.16% (95% CI: 0.13%-0.19%) and 0.13% (95% CI: 0.11%-0.16%), respectively. These reductions were associated with lower odds of insulin use over time, ranging from 21% lower odds for a 5% reduction in percent body fat to 32% lower odds for 5% reductions in waist circumference and BMI. Associations were evident across subgroups defined by sex, diabetes duration, obesity status, and intervention assignment.
Conclusions: Reductions in adiposity are associated with stabilized and slightly lower HbA1c and a marked reduction in the need for insulin therapy. These benefits generalize across clinical subgroups.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11897852 | PMC |
| http://dx.doi.org/10.1002/oby.24242 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical Outcomes and Complications of Basal, Bolus, and Combination Insulin Regimens in Type 2 Diabetes Mellitus: Evidence from Published Case Reports.
Diabetes Metab Syndr Obes
September 2025
Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, Indonesia.
Insulin therapy remains a cornerstone in the management of type 2 diabetes mellitus (T2DM), especially in patients experiencing progressive loss of pancreatic beta-cell function or those with inadequate glycemic control despite oral antidiabetic therapy. This review synthesized clinical outcomes from 44 peer-reviewed case reports published between 2019 and 2024, identified through systematic searches in PubMed and Scopus. The included cases involved 15 males and 29 females, with patient ages ranging from 11 to 91 years (mean 53 ± 20.
View Article and Find Full Text PDFPrevalence and Associated Factors of Hypoglycemia Among Patients With Type 2 Diabetes Mellitus: A Cross-Sectional Study.
Cureus
August 2025
Department of Family Medicine, Akram and Rasool Hospital, Sarai Alamgir, PAK.
Background: Patients with type 2 diabetes mellitus (T2DM) often experience hypoglycemia, an underappreciated consequence that has a major negative influence on treatment compliance and quality of life.
Objective: This study aimed to determine the prevalence and associated factors of hypoglycemia among patients with T2DM, with a focus on treatment types, comorbidities, and glycemic control. By providing population-specific data, the study intends to inform clinical decision-making and contribute to safer, more personalized diabetes management strategies.
Hypoglycemia incidence and behavioural adjustments during free-living unstructured physical activity in adults with type 1 diabetes using AID systems: Results from the RAPPID study.
Diabetes Obes Metab
September 2025
Diabetes Care Unit, Nancy University Hospital, Nancy, France.
Aims: To assess the frequency and management of hypoglycaemia during unstructured physical activity (PA) in adults with type 1 diabetes (T1D) using automated insulin delivery (AID) systems in real-life settings.
Materials And Methods: RAPPID is a prospective, multicenter, observational study conducted over 1 month in four French tertiary care centres. Adults with T1D using one of three AID systems (MiniMed 780G, Tandem t:slim X2 with Control-IQ, or Ypsopump with CamAPS FX) and performing ≥2 unstructured PA sessions per week were included.
Long-term efficacy and safety of tirzepatide in participants with type 2 diabetes with inadequate glycaemic control on metformin and/or sulfonylurea: Post-hoc analysis of SURPASS-4.
Diabetes Obes Metab
September 2025
Department of Endocrinology, Peking University People's Hospital, Beijing, People's Republic of China.
Aim: To evaluate the long-term efficacy and safety data at 104 weeks in tirzepatide-treated participants with type 2 diabetes who had inadequate glycaemic control on metformin and/or sulfonylurea.
Materials And Methods: This post-hoc analysis was based on the SURPASS-4 data (NCT03730662), a multicenter, Phase III trial. Participants were randomised to receive tirzepatide (5, 10, or 15 mg) or insulin glargine.
Impact of Omnipod 5 automated insulin delivery on continuous glucose monitoring metrics and predictors of improvement in time in range.
Diabet Med
September 2025
Edinburgh Centre for Endocrinology & Diabetes, NHS Lothian, Edinburgh, UK.
Aims: This study aimed to assess the impact of the Omnipod 5 automated insulin delivery (AID) system on continuous glucose monitoring (CGM) metrics, HbA1c, and weight in a real-world setting. Additionally, independent predictors of glycaemic response were assessed.
Methods: Observational analysis of adults with type 1 diabetes using Omnipod 5 (n = 353).